CLAIM CARD
The corpus includes multiple study designs evaluating rapamycin's effects on immune function, ranging from preclinical mechanistic work to observational cohorts and systematic reviews. In older adults, randomized to receive 1 mg/day rapamycin or placebo, Kell 2026 examined geroprotective effects on the ageing human immune system with a focus on DNA damage resilience. Jurdi 2025 evaluated sirolimus use in allogeneic hematopoietic cell transplant recipients, a high-risk population experiencing accelerated aging and cellular senescence from chemotherapy exposure.
Evidence grade: exploratory
Contradiction status: none
Publication: f02d4a53-03e5-47ed-9876-75a416e3bd24
Provenance: Derivation Web chain
Citation Support
source_1Moel 2025source_2Gkioni 2025source_3Smiaek 2023source_4Willows 2023source_5Harinath 2025